

Soňa Balogová

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4808994/publications.pdf>

Version: 2024-02-01

46
papers

1,730
citations

430874

18
h-index

276875

41
g-index

63
all docs

63
docs citations

63
times ranked

1851
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic Cavernous Hemangioma Mimicking Metastasis of Midgut Neuroendocrine Neoplasia on 18F-Fluorodihydroxyphenylalanine PET/CT. <i>Clinical Nuclear Medicine</i> , 2022, 47, 76-78.	1.3	2
2	Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT, illustrative cases and pitfalls. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , .	0.7	3
3	Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication. <i>Clinical Nuclear Medicine</i> , 2022, 47, 305-313.	1.3	11
4	Nuclear endocrinology in the era of precision medicine. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , .	0.7	0
5	Stage I testicular seminoma risk-adapted therapeutic management. <i>Neoplasma</i> , 2021, 68, 613-620.	1.6	1
6	Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. <i>BMC Medical Imaging</i> , 2020, 20, 25.	2.7	10
7	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	6.4	208
8	Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. <i>Neoplasma</i> , 2019, 66, 140-148.	1.6	9
9	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. <i>PLoS ONE</i> , 2018, 13, e0191487.	2.5	18
10	Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy. <i>Nuclear Medicine Review</i> , 2018, 21, 26-31.	0.5	5
11	FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring. <i>Blood</i> , 2018, 132, 4487-4487.	1.4	0
12	Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-â€œDOPA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1588-1601.	6.4	319
13	Reply. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 172-172.	6.4	0
14	32nd International Austrian Winter Symposium. <i>EJNMMI Research</i> , 2016, 6, 32.	2.5	0
15	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1995-2004.	6.4	67
16	Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1220-1230.	6.4	7
17	Controversies in the management of clinical stage I testicular seminoma. <i>Central European Journal of Urology</i> , 2016, 69, 35-9.	0.3	2
18	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism. <i>Medicine (United States)</i> , 2015, 94, e1701.	1.0	145

#	ARTICLE	IF	CITATIONS
19	Is 18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography a New Imaging Tool for Detecting Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4531-4536.	3.6	132
20	Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. Clinical Nuclear Medicine, 2014, 39, 951-959.	1.3	10
21	Incidental uptake of ¹⁸ F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiology and Oncology, 2014, 48, 228-234.	1.7	44
22	Use of choline PET for studying hepatocellular carcinoma. Clinical and Translational Imaging, 2014, 2, 103-113.	2.1	17
23	Signification dâ€™une hyperfixation prostatique du fluorodÃ©soxyglucose (18F) chez un patient sans antÃ©cÃ©dent de cancer de la prostate. Cas cliniques, revue et mÃ©ta-analyse de la littÃ©rature. Medecine Nucleaire, 2014, 38, 266-274.	0.2	1
24	Strengths and limitations of using 18fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. Expert Review of Endocrinology and Metabolism, 2014, 9, 477-485.	2.4	1
25	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. Radiology and Oncology, 2014, 48, 20-28.	1.7	8
26	18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 943-966.	6.4	101
27	Effect of Erythropoietin on Bone Marrow Uptake of 18F-Fluorocholine in Prostate Cancer. Clinical Nuclear Medicine, 2013, 38, 200-202.	1.3	12
28	Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality?. Nuclear Medicine Communications, 2013, 34, 417-425.	1.1	21
29	Metabolic syndrome and its effect on aortic stiffness in premenopausal women. Bratislava Medical Journal, 2013, 114, 279-282.	0.8	3
30	What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?. Current Radiopharmaceuticals, 2013, 6, 96-105.	0.8	29
31	Registered and potential indications of FDG PET/CT in breast carcinoma. Archive of Oncology, 2012, 20, 152-157.	0.2	0
32	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nuclear Medicine Communications, 2012, 33, 757-765.	1.1	22
33	Ã‰volution de la demande des examens de mÃ©decine nuclÃ©aire pour cancer de la prostate depuis lâ€™enregistrement de la fluorocholine (18F)Ã: analyse sur deux ans Ã lâ€™hÃ´pital Tenon. Medecine Nucleaire, 2012, 36, 363-370.	0.2	2
34	Ã‰tude rÃ©trospective des consÃ©quences de lâ€™administration dâ€™une prÃ©paration de FDG contenant de 5Ã% Ã 10Ã% de fluorure (18F) libre sur lâ€™imagerie TEP/TDM de lâ€™os sain et des foyers osseux pathologiques. Comparaison avec un groupe appariÃ© de patients ayant reÃ§u une prÃ©paration de FDG contenant moins de 5Ã% de fluorure (18F) libre. Medecine Nucleaire, 2012, 36, 371-377.	0.2	0
35	TEP/TDM au FDG et hibernomeÃ: Ã propos dâ€™un cas. Medecine Nucleaire, 2012, 36, 408-412.	0.2	0
36	Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 374-410.	0.7	36

#	ARTICLE	IF	CITATIONS
37	Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 448-57.	0.7	76
38	Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nuclear Medicine Communications, 2010, 31, 389-397.	1.1	45
39	Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of ¹⁸ F-Fluorocholine and ¹⁸ F-FDG in Patients with Cirrhosis or Chronic Liver Disease. Journal of Nuclear Medicine, 2010, 51, 1699-1706.	5.0	183
40	Tomographie dâ€™mission de positons et radiopharmaceutiques spÃ©cifiques en oncologieÂ: exemples dâ€™application. Medecine Nucleaire, 2009, 33, 152-160.	0.2	1
41	TEP/TDM au fluorure (18F) de sodium pour la dÃ©tection des mÃ©tastases osseuses du cancer de la prostate. Description de lâ€™Ã©tude Fluprostatic de comparaison de la TEP/TDM au fluorure (18F) de sodium Ã lâ€™IRM corps entierÂ dans cette indication. Medecine Nucleaire, 2009, 33, 388-397.	0.2	3
42	Prospective Comparison of FDG and FET PET/CT in Patients with Head and Neck Squamous Cell Carcinoma. Molecular Imaging and Biology, 2008, 10, 364-373.	2.6	33
43	Tomographie par Ã©mission de positons et cancer de la prostate. Medecine Nucleaire, 2008, 32, 409-417.	0.2	6
44	Impact of FDGâ€PET to detect recurrence of head and neck squamous cell carcinoma. Otolaryngology - Head and Neck Surgery, 2007, 137, 647-653.	1.9	30
45	TEP/TDM Ã la fluoromÃ©thylcholine-(18F) dans lâ€™imagerie de la rÃ©cidive du cancer de la prostateÂ: jalons pour un PHRC national. Medecine Nucleaire, 2007, 31, 338-344.	0.2	1
46	Positron emission tomography with [18F]FDOPA and [18F]FDG in the imaging of small cell lung carcinoma: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1266-1269.	6.4	37